From germ theory to germ therapy
- PMID: 30848026
- DOI: 10.1002/kjm2.12011
From germ theory to germ therapy
Abstract
Germ theory of disease and Koch's postulates has been governing our understanding of the role of microbes in human health since 19th century. The discovery of Helicobacter pylori (H. pylori) and H. pylori associated diseases has typically represented the concept and framework of Koch's postulates. Eradication of H. pylori to prevent peptic ulcers recurrence and gastric cancer is the triumph of this microbiology paradigm. Advances of next generation sequencing provide great insight into the unculturable microbes and show trillions of microbes have evolved with human beings. Research into the microbiome-the microbial communities (microbiota) and the host environment that they inhabit-has changed our understanding about microbes in human health and disease. The gut microbiota, the largest reservoir of the microbiome in human, plays a critical role in our catabolic-metabolism and immunity. This review will show the changes of the view of microbes on human health. We will briefly discuss dysbiosis, the disruption of symbiotic relationship between the host and microbiota, and the associated diseases. This leads to an idea to manipulate the microbiota, either by restoring missing functions or by eliminating harmful functions, to prevent or treat a variety of diseases. Current evidences of two common germ therapies, fecal microbiota transplantation and probiotics, in treating diseases will be reviewed.
Keywords: Helicobacter pylori; fecal microbiota transplantation; microbiota; probiotics.
© 2019 The Authors. Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.
Similar articles
-
The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial.Helicobacter. 2016 Jun;21(3):165-74. doi: 10.1111/hel.12270. Epub 2015 Sep 23. Helicobacter. 2016. PMID: 26395781 Clinical Trial.
-
The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.Pharmacol Ther. 2015 May;149:191-212. doi: 10.1016/j.pharmthera.2014.12.006. Epub 2015 Jan 3. Pharmacol Ther. 2015. PMID: 25561343 Review.
-
Microbial modulation of the gut microbiome for treating autoimmune diseases.Expert Rev Gastroenterol Hepatol. 2018 Oct;12(10):985-996. doi: 10.1080/17474124.2018.1517044. Epub 2018 Sep 3. Expert Rev Gastroenterol Hepatol. 2018. PMID: 30146910 Review.
-
Gut microbiota in the pathogenesis of inflammatory bowel disease.Clin J Gastroenterol. 2018 Feb;11(1):1-10. doi: 10.1007/s12328-017-0813-5. Epub 2017 Dec 29. Clin J Gastroenterol. 2018. PMID: 29285689 Review.
-
Antibiotic and Modulation of Microbiota: A New Paradigm?J Clin Gastroenterol. 2018 Nov/Dec;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017:S74-S77. doi: 10.1097/MCG.0000000000001069. J Clin Gastroenterol. 2018. PMID: 29912755
Cited by
-
Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover.Front Genet. 2022 Aug 9;13:921972. doi: 10.3389/fgene.2022.921972. eCollection 2022. Front Genet. 2022. PMID: 36017495 Free PMC article. Review.
-
Dose-Dependent Relationship between Protection of Thioacetamide-Induced Acute Liver Injury and Hyperammonemia and Concentration of Lactobacillus salivarius Li01 in Mice.Microbiol Spectr. 2021 Dec 22;9(3):e0184721. doi: 10.1128/spectrum.01847-21. Epub 2021 Dec 22. Microbiol Spectr. 2021. PMID: 34937168 Free PMC article.
-
Possible opportunities and challenges for traditional Chinese medicine research in 2035.Front Pharmacol. 2024 Jun 21;15:1426300. doi: 10.3389/fphar.2024.1426300. eCollection 2024. Front Pharmacol. 2024. PMID: 38974044 Free PMC article.
Publication types
MeSH terms
Grants and funding
- NTUH 106-P06/National Taiwan University Hospital
- NTUH 104-P05/National Taiwan University Hospital
- 107-0210-01-19-04/Translational Innovation of Biopharmaceutical Development-Technology Supporting Platform Axis
- MOHW107-TDU-B-211-123 002/Ministry of Health and Welfare of Taiwan
- MOHW106-TDU-B-211-113 002/Ministry of Health and Welfare of Taiwan
LinkOut - more resources
Full Text Sources